Why Juno Therapeutics Stock Is Blasting Off Today
Shares of Juno Therapeutics (NASDAQ: JUNO) are up by double digits for the second day in a row on extremely heavy volume. The catalyst behind this continued surge higher is the nearly $12 billion buyout of rival adoptive cell therapy company Kite Pharma (NASDAQ: KITE) by Gilead Sciences (NASDAQ: GILD) yesterday.
As of 1:26 p.m. EDT, investors have already bid up Juno's shares by another 18%. If this sizable move northward holds -- and all signs indicate that it will -- Juno's shares will end up gaining 40% in just the first two trading sessions of this week.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Aktie
74,31 €
-1,09 %
Einseitige Zustimmung für Gilead Sciences Inc mit mehreren Buy- und keiner Sell-Einschätzung.
Das Kursziel von 85 € für Gilead Sciences Inc weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 74.31 € hin.
